 Maxim Group reiterated their buy rating on shares of Capricor Therapeutics NASDAQ:CAPR in a report released on Friday morning, AnalystRatings.com reports. Maxim Group currently has a 4.00 target price on the biotechnology companys stock. A number of other research firms also recently weighed in on CAPR. ValuEngine raised shares of Capricor Therapeutics from a hold ... 